Crystagen: Reference Overview and Reconstitution Notes

Crystagen is a short man-made peptide (a tiny chain of three amino acids) from the Khavinson bioregulator family. It is grouped as an immune research compound and is offered on a research-only basis. It has not been approved by the FDA.

Crystagen

What it is

Crystagen is a man-made short peptide. A peptide is a small chain of building blocks called amino acids. Crystagen has just three of them, so it is called a tripeptide. Think of it like a three-bead necklace. The three beads, in order, are glutamic acid, aspartic acid, and proline (Glu-Asp-Pro). It belongs to a group called Khavinson peptide bioregulators, a set of short peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology. Crystagen is part of a line known as the synthetic "Cytogen" thymus peptides.

Research context and categorization

Immune System Research

Crystagen is grouped as an immune bioregulator. That means researchers study how it may interact with the immune system (the body's defense network). It is most often discussed in connection with the thymus, a small gland that helps train immune cells. Crystagen is modeled on small peptide pieces linked to thymus activity.

In laboratory and animal studies, researchers have looked at how Crystagen interacts with thymocytes (cells that live in the thymus) and T-lymphocyte populations (a type of immune cell the thymus produces). Scientists also study it in the context of gene-expression regulation. Gene expression is the process by which genes are read and used to build proteins. The Khavinson model suggests that short peptides like Crystagen may interact with DNA and influence this process.

These are early-stage research topics. All findings come from cell cultures and animal models. No effects have been confirmed or approved in humans. Crystagen is not an approved therapy. Any results discussed in the literature should be treated as unproven and preliminary.

Key point: Crystagen is strictly an investigational compound (a substance still being studied, not approved for use). It is not approved for human clinical use or medical treatment.

Status

• Regulatory status: Research-only. Crystagen is not FDA-approved for any purpose and is handled as an investigational research compound, not a medicine.
• Sport status: Crystagen is not listed by name on the WADA Prohibited List. (WADA is the World Anti-Doping Agency, which sets the rules on banned substances in sport.) Note that WADA can treat an unnamed substance as prohibited if it falls within a banned class or shares a similar structure or biological effect. The absence of a named listing is not a clearance. Anyone competing under anti-doping rules should verify current status directly with the relevant authority.

Reconstitution notes (general)

Crystagen is supplied as a lyophilized (freeze-dried) powder. Before it can be used at the lab bench, the dry powder must be mixed with a liquid to make a solution. This process is called reconstitution. The concentration (how much peptide is in each milliliter of liquid) depends on how much powder is in the vial and how much liquid you add.

• Concentration formula: Milligrams of peptide in the vial divided by milliliters of bacteriostatic water added.
• Example: 20 mg of powder mixed with 2 mL of bacteriostatic water gives a concentration of 10 mg per mL.

A reconstitution calculator is available at peptide calculator to work out the volume for a target concentration.

Dilution and handling notes (compound-specific)

Dissolution Properties

Because Crystagen is a very small peptide and dissolves easily in water, it typically mixes into a clear, colorless solution quickly. It does not tend to cloud up, gel, or form particles the way some larger or less water-friendly peptides can at higher concentrations.

Reconstitution Steps

• Add the water slowly down the inner wall of the vial.
• Let it stand and swirl gently rather than shaking. Shaking mainly creates foam and puts mechanical stress on the peptide without helping it dissolve any faster.
• Vials are commonly offered in roughly the 5 mg to 20 mg range. Reconstitution volumes of about 2 mL to 3 mL are typically chosen to reach a convenient working concentration.

The finished solution should look completely clear. Any persistent cloudiness, haze, visible particles, or floating bits after gentle mixing points to a material or handling problem, not normal behavior for this compound. Because Crystagen is a short peptide (not a tablet, small molecule, or pre-mixed liquid), it does need to be reconstituted before use in a research lab setting.

Handling and storage

To keep the peptide in good condition, follow these storage and handling steps:

• Store the reconstituted solution in the refrigerator at 2 to 8 °C, away from direct light.
• Wipe the vial stopper with an alcohol swab before drawing from it each time.
• Write the mix date on the vial label so you always know how old the solution is. A refrigerated working window of roughly four weeks is a common reference point.
• Discard the solution if it turns cloudy or discolored, or if visible particles or floaters appear.
• Keep the lyophilized (unreconstituted) powder frozen, sealed, and protected from light and moisture for longer-term storage.

Related reading

• Dermorphin
• DSIP (Delta Sleep-Inducing Peptide)
• Epitalon
• How Reconstitution Works
• How Long Does a Reconstituted Vial Last?

Tools and supplies

• peptide calculator
• Bacteriostatic Water 30 ml
• Gansulin Metal Reusable Pen
• 3 ml Glass Cartridges (10-pack)
• Complete Starter Kit

Reminder: research and educational reference only. Preppin Peppers sells hardware and materials, not peptides. Not medical, dosing, or health advice, not evaluated by the FDA, and not intended for human or animal use.

Frequently asked questions

What is Crystagen and what amino acids does it contain?

Crystagen is a synthetic tripeptide composed of glutamic acid, aspartic acid, and proline (Glu-Asp-Pro). It belongs to the Khavinson peptide bioregulator family and is handled as an investigational research compound only.

How is Crystagen reconstituted for laboratory use?

Divide milligrams of lyophilized powder by milliliters of bacteriostatic water added to calculate concentration (e.g., 20 mg ÷ 2 mL = 10 mg/mL). Add solvent slowly, swirl gently, and verify clarity before lab bench use.

Is Crystagen listed on the WADA Prohibited List?

Crystagen is not named on the current WADA Prohibited List. However, WADA may prohibit unnamed substances sharing a banned class, structure, or biological effect. Always verify status directly with the relevant anti-doping authority.

What the research community gets wrong about Crystagen

• Its sequence gets mixed up. Product pages sometimes list Crystagen as different amino acids (for example Thr-Lys-Asp). In the Khavinson literature it is described as the tripeptide Glu-Asp-Pro (often written EDP). When you label a vial or log a sample, match it to the EDP sequence and its PubChem record, not to a vendor blurb.
• "Bioregulator" is treated like proven biology. The idea that a short peptide like EDP slips into the nucleus and binds a specific DNA sequence comes from molecular modeling and docking studies, not from confirmed high-resolution structures. It is a proposed model, so treat it as a hypothesis to test at the bench, not a settled fact.
• People assume the immune findings are established. Reports on thymocytes and T-cell populations come from cell cultures and animal work, and most trace back to a single research group. None of it is FDA-approved or confirmed in people, so it does not tell you what a sample will do in any other system.
• Crystagen and Thymalin get treated as the same thing. Crystagen (EDP) is one short synthetic peptide that has been discussed as a component tied to thymus extracts. It is not the whole extract, and mixing up the two makes literature comparisons unreliable.
• More mixing is thought to help it dissolve. EDP is a very small, water-friendly peptide that usually goes into a clear solution fast. Shaking mostly makes foam and adds mechanical stress. Adding water slowly down the vial wall and swirling gently is enough.

From our bench: If you have reconstituted a Crystagen (EDP) vial, we want your real observation on dissolution. Adding bacteriostatic water slowly down the wall and swirling gently, how many seconds or minutes passed before the powder went fully clear, and did any haze or floaters show up afterward? Note your vial size, the volume of water you added, and your storage temperature, and send us the actual numbers you recorded (no estimates).

Sources

1. Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
2. Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
3. Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
4. Glu-Asp-Pro (tripeptide), PubChem CID 145455337, National Library of Medicine
5. Khavinson, Lin'kova, Tarnovskaya (2016), Short Peptides Regulate Gene Expression, Bull Exp Biol Med (documents EDP DNA binding), PubMed 27909961
6. Khavinson, Kuznik, Ryzhak (2013), Peptide bioregulators: the new class of geroprotectors. Clinical studies results, Adv Gerontol, PubMed 24003726